Clinical Trial Results:
            A   Phase III,  Randomised,  Double-blind,  Multi-centre, Withdrawal Study comparing MCI-196 versus Placebo in Chronic Kidney Disease Stage V Subjects on Dialysis with Hyperphosphataemia (Incorporating a Randomised 12 Week Open-label Dose Titration Period with MCI-196 or Sevelamer)
    
    Due to the EudraCT – Results system being out of service between 31 July 2015 and 12 January 2016, these results have been published in compliance with revised timelines
|     Summary | |
|     EudraCT number | 2006-003323-37 | 
|     Trial protocol | HU AT CZ FR DE IT GB | 
|     Global completion date | 
                                    11 Nov 2009
                             | 
|     Paediatric regulatory details | |
|     Is the trial part of an agreed EMA paediatric investigation plan? | 
                                        No
                                 | 
|     Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Results information | |
|     Results version number | v1(current) | 
|     This version publication date | 
                                    02 Nov 2016
                             | 
|     First version publication date | 
                                    02 Nov 2016
                             | 
|     Other versions | |
|     Summary report(s) | ClinTrials.gov receipt_MCI-196-E07 | 
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.    
 
				
